Interleukin 13 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Interleukin-13 (IL-13) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Interleukin-13 (IL-13) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Interleukin-13 (IL-13) Inhibitors: Overview
IL-13 is an important cytokine in chronic airways inflammation. IL-13 is involved in Th2 inflammation and has been identified as a possible therapeutic target in the treatment of asthma and allergies. IL-13 gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines.
Function – IL-13 is a 132-amino-acid nonglycosylated cytokine that shares common features with IL-4. IL-13 inhibits TNF, IL-1, IL-8, and MIP-1a production, NF-kB activation and CD14 and Fcg receptor expression. It induces cell surface expression of b2 integrins and MHC class II antigens. IL-13 appears to play a profibrotic role in the aging heart. Interleukin (IL)-13 is a cytokine that also represents a potential critical factor in the development and persistence of asthma.
Interleukin-13 (IL-13) Inhibitors- As interleukin (IL)-13 play a major role in various diseases including asthma, allergy, and malignancies, it is desirable to generate a molecule that blocks this cytokine. IL-13 inhibitor inhibits IL-4 binding to these cells and prevents heterodimer formation between IL-13Ralpha1 and IL-4Ralpha chains. This interference by IL-13 inhibitor blocks the biological activities of not only IL-13 but also partially of IL-4. Thus, IL-13 inhibitor may be a useful agent for the treatment of diseases such as asthma, allergic rhinitis, and cancer, which are dependent on signaling through both IL-4 and IL-13 receptors.
Interleukin-13 (IL-13) Inhibitors Emerging Drugs Chapters
This segment of the Interleukin-13 (IL-13) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin-13 (IL-13) Inhibitors Emerging Drugs
Further product details are provided in the report……..
Interleukin-13 (IL-13) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin-13 (IL-13) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Interleukin-13 (IL-13) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interleukin-13 (IL-13) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-13 (IL-13) Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Interleukin-13 (IL-13) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Interleukin-13 (IL-13) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Interleukin-13 (IL-13) Inhibitors: Overview
IL-13 is an important cytokine in chronic airways inflammation. IL-13 is involved in Th2 inflammation and has been identified as a possible therapeutic target in the treatment of asthma and allergies. IL-13 gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines.
Function – IL-13 is a 132-amino-acid nonglycosylated cytokine that shares common features with IL-4. IL-13 inhibits TNF, IL-1, IL-8, and MIP-1a production, NF-kB activation and CD14 and Fcg receptor expression. It induces cell surface expression of b2 integrins and MHC class II antigens. IL-13 appears to play a profibrotic role in the aging heart. Interleukin (IL)-13 is a cytokine that also represents a potential critical factor in the development and persistence of asthma.
Interleukin-13 (IL-13) Inhibitors- As interleukin (IL)-13 play a major role in various diseases including asthma, allergy, and malignancies, it is desirable to generate a molecule that blocks this cytokine. IL-13 inhibitor inhibits IL-4 binding to these cells and prevents heterodimer formation between IL-13Ralpha1 and IL-4Ralpha chains. This interference by IL-13 inhibitor blocks the biological activities of not only IL-13 but also partially of IL-4. Thus, IL-13 inhibitor may be a useful agent for the treatment of diseases such as asthma, allergic rhinitis, and cancer, which are dependent on signaling through both IL-4 and IL-13 receptors.
Interleukin-13 (IL-13) Inhibitors Emerging Drugs Chapters
This segment of the Interleukin-13 (IL-13) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Interleukin-13 (IL-13) Inhibitors Emerging Drugs
- Tralokinumab: Leo Pharma
- Dupilumab: Regeneron/Sabofi
Further product details are provided in the report……..
Interleukin-13 (IL-13) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Interleukin-13 (IL-13) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Interleukin-13 (IL-13) Inhibitors
- Phases
- Late-stage products (Phase III )
- Mid-stage products (Phase II )
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intravenous
- Intramuscular
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Interleukin-13 (IL-13) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Interleukin-13 (IL-13) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Interleukin-13 (IL-13) Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Interleukin-13 (IL-13) Inhibitors R&D.
- The therapies under development are focused on novel approaches for Interleukin-13 (IL-13) Inhibitors.
- Interleukin-13 (IL-13) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Interleukin-13 (IL-13) Inhibitors drugs?
- How many Interleukin-13 (IL-13) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Interleukin-13 (IL-13) Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Interleukin-13 (IL-13) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Interleukin-13 (IL-13) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Interleukin-13 (IL-13) Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Interleukin-13 (IL-13) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Interleukin-13 (IL-13) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin-13 (IL-13) Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Tralokinumab: Leo Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Romilkimab: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AZD 0449: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin-13 (IL-13) Inhibitors Key Companies
Interleukin-13 (IL-13) Inhibitors Key Products
Interleukin-13 (IL-13) Inhibitors- Unmet Needs
Interleukin-13 (IL-13) Inhibitors- Market Drivers and Barriers
Interleukin-13 (IL-13) Inhibitors- Future Perspectives and Conclusion
Interleukin-13 (IL-13) Inhibitors Analyst Views
Interleukin-13 (IL-13) Inhibitors Key Companies
Appendix
Executive Summary
Interleukin-13 (IL-13) Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Interleukin-13 (IL-13) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Interleukin-13 (IL-13) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Interleukin-13 (IL-13) Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Preregistration)
Comparative Analysis
Tralokinumab: Leo Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Romilkimab: Sanofi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AZD 0449: AstraZeneca
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Interleukin-13 (IL-13) Inhibitors Key Companies
Interleukin-13 (IL-13) Inhibitors Key Products
Interleukin-13 (IL-13) Inhibitors- Unmet Needs
Interleukin-13 (IL-13) Inhibitors- Market Drivers and Barriers
Interleukin-13 (IL-13) Inhibitors- Future Perspectives and Conclusion
Interleukin-13 (IL-13) Inhibitors Analyst Views
Interleukin-13 (IL-13) Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Interleukin-13 (IL-13) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Interleukin-13 (IL-13) Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Interleukin-13 (IL-13) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Interleukin-13 (IL-13) Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
